Pharma channel feed

Bob Nelsen ex­its board and pres­i­dent steps down at Uni­ty as fall­out from the an­ti-ag­ing biotech's PhII miss con­tin­ues

5 years ago
People

At­tor­neys gen­er­al ask HHS to pun­ish 340B pro­gram bilk­ers — but phar­ma claims it's fight­ing 'waste and abuse'

5 years ago

Vi­a­tris plans across-the-board cuts that could en­dan­ger 9,000 work­ers, 15 plants in post-merg­er re­struc­tur­ing scheme

5 years ago

De­spite flop­ping piv­otal tri­al, No­var­tis' En­tresto will face ad­comm fir­ing line for holy grail heart fail­ure pa­tients

5 years ago
FDA+

Re­call re­port: AvKARE some­how mixed its an­ti­de­pres­sant and erec­tile dys­func­tion meds; Tor­rent pulls throm­bo­cy­to­sis drug

5 years ago
FDA+

Alk­er­mes CEO Richard Pops wins over ac­tivists with a pledge to shake up the com­pa­ny and boost net in­come

5 years ago

New York law­suit again ac­cus­es Mar­tin Shkre­li of ma­nip­u­la­tion from be­hind bars

5 years ago
People

No­var­tis' CDK4/6 med Kisqali, firm­ly the sales un­der­dog against Pfiz­er's Ibrance, drops big OS da­ta

5 years ago
R&D

Ab­b­Vie chas­es its next gold­en goose in a post-Hu­mi­ra fu­ture with new ul­cer­a­tive col­i­tis da­ta for Rin­voq

5 years ago
R&D

Seat­tle's AGC plots $194M in­vest­ment to dou­ble pro­duc­tion at Copen­hagen site in busy year for bi­o­log­ics

5 years ago
Outsourcing
Coronavirus

#ASH20 saw a BC­MA brawl. Who's still stand­ing? And who got knocked out for good?

5 years ago
R&D

Zio­phar­m's ac­tivist dra­ma con­tin­ues as an­oth­er board mem­ber mem­ber re­signs. Is the end in sight?

5 years ago

BioCryst wins ap­proval for HAE pill and charges half-a-mil­lion dol­lars, but will any­one take it?

5 years ago
FDA+

Mer­ck sells off its Mod­er­na stake af­ter mak­ing record gains amid the pan­dem­ic

5 years ago

Roche turns up the heat on Lil­ly with an­oth­er Gavre­to ap­proval, el­bow­ing its way in­to the thy­roid can­cer space

5 years ago
FDA+

Long af­ter Mer­ck and Bris­tol My­ers cre­at­ed a multi­bil­lion-dol­lar mar­ket, the PD-1 lead­ers are once again duk­ing it out — this time over a $12B-plus pot

5 years ago
R&D

Bay­er con­tin­ues its cell and gene ther­a­py push, en­velop­ing dif­fer­ent projects un­der one strate­gic roof while hunt­ing new deals

5 years ago
Cell/Gene Tx

Not so fast, Mr Pres­i­dent: Trump's plan for low­er­ing pre­scrip­tion drug prices hits a road­block, as Cana­da bans bulk drug ex­ports

5 years ago
People

Zio­pharm and a mi­nor­i­ty in­vestor spent Thanks­giv­ing fight­ing over con­trol of the com­pa­ny as ac­tivist at­tack con­tin­ues to un­fold

5 years ago

Shop­ping for a hol­i­day pipeline gift? How about an an­ti-NGF an­ti­body from Astel­las?

5 years ago

Bax­ter con­tin­ues on-shoring push with $50M In­di­ana ex­pan­sion

5 years ago
Outsourcing

Eu­ro­pean Union aims to es­tab­lish patent workaround in case of emer­gen­cies while try­ing to strength­en its own IP

5 years ago

Pur­due Phar­ma pleads guilty in fed­er­al Oxy­Con­tin probe, for­mal­ly rec­og­niz­ing it played a part in the opi­oid cri­sis

5 years ago

PhRMA sues Trump gov­ern­ment over drug im­por­ta­tion rule — days be­fore it's set to be ef­fec­tive

5 years ago
First page Previous page 248249250251252253254 Next page Last page
A service from the Financial Times